Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-Griffithsin Intranasal Spray for Coronavirus Prophylaxis
NCT05437029Phase 1Unknown
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of q-griffithsin in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Pharmacokinetic levels and Safety of product. Status: unknown.
02
Drugs
q-griffithsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05437029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437029.